In recent years, as advances in technologies have facilitated the generation of genomic information, we have witnessed an unprecedented explosion of pharmacogenomic discoveries. However, only a small number of these discoveries have made their way into clinical practice. There are several barriers to successful clinical implementation. First, a high-quality genotyping assay with rapid turnaround time is required. Second, the appropriate interpretation of pharmacogenetic test results by busy clinicians requires an adequate clinical decision support infrastructure, and the rapid advances in the field of pharmacogenomics may underscore the need for adequate training for healthcare professionals \[[@B1]\]. Last, the absence of a standardized framework for incorporating pharmacogenomic discoveries into diagnostic tests and therapeutic strategies is currently a major obstacle. Among the efforts aimed at addressing this gap, a recent article by Gharani and colleagues \[[@B2]\], published in *Genome Medicine*, presents the Pharmacogenomics Appraisal, Evidence Scoring and Interpretation System (PhAESIS), and its application to seven commonly prescribed drugs.

The PhAESIS framework
=====================

PhAESIS is a multi-purpose framework that identifies genetic factors with sufficiently robust evidence for contributing to drug response and provides guidelines for translating such genotype information into therapeutic recommendations. PhAESIS was developed by the Coriell Personalized Medicine Collaborative (CPMC) to guide the identification of genetic variants that are significantly associated with an elevated risk of adverse drug reactions; the ultimate goal is to translate pharmacogenomic findings into tailored therapy for patients. Genetic factors are identified based on a critical appraisal of pharmacologic studies. Furthermore, the framework provides recommendations for the clinical implementation of study findings and identifies gaps in knowledge for future investigation.

As the authors acknowledge, CPMC is not alone in its efforts to develop a system that converts the enormous number of published pharmacogenomic studies into clear and evidence-based therapeutic guidelines for clinical practice. Several well-known consortia, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) \[[@B3]\], the Pharmacogenetics Working Group (PWG) \[[@B4]\], and Evaluation of Genomic Applications in Practice and Prevention (EGAPP) \[[@B5]\], are also developing guidelines. Each consortium has its strengths and weaknesses, some of which are covered in the study by Gharani *et al*. The CPMC framework aims to reflect a broader representation of the parties involved (for example, healthcare professionals and health consumers) and a more refined definition of the clinical relevance of pharmacogenomic findings (such as the distinction between genetic variants with published clinical outcome data and genetic variants with *in vitro* support for protein function).

There are opportunities for improvement. For example, the approach, in its current form, is quite gene- and function-centric. Only genetic variants deemed functional or located in genes were selected in the scoring system. It is of course true that most pharmacogenomic studies that have shown clinical relevance have, to date, focused primarily on genes. However, this merely reflects the history of pharmacogenomic research and may not be biologically informed. Indeed, large numbers of non-coding genetic variants have now been shown to be reproducibly associated with clinical phenotypes \[[@B6]\] by genome-wide association studies, although their underlying mechanisms remain to be fully elucidated. Therefore, the inclusion of such genetic variants into the PhAESIS system is highly desirable from a clinical standpoint and likely to be necessary even as we await their full characterization. Furthermore, we believe PhAESIS must eventually come to terms with the growing importance of high-throughput molecular phenotypes (for example, quantitative measurements of the transcriptome or the proteome) and their potential implications for diagnostic and clinical use.

Future implications for clinical practice
=========================================

In this age of rapid advances in genomic research, it is critical to develop a precise and standardized approach to identify clinically relevant genomic loci and facilitate the translation of this information into the clinic. The study by Gharani *et al*. is therefore very timely. There are several clear strengths in the work presented. For example, the inclusion of a multi-tier evidence scoring system that enables a comprehensive appraisal of the clinical evidence and the routine incorporation of pharmacogenomic findings into clinical practice are primary emphases of the framework. Detailed information provided in the supplemental materials may be useful in providing guidelines for specific drug-gene cases. The authors have demonstrated the application of PhAESIS for the identification of key genes associated with adverse reactions for seven widely prescribed drugs (clopidogrel and *CYP2C19*; warfarin and *CYP2C9*, *VKORC1* and *CYP4F2*; proton pump inhibitors and *CYP2C19*; codeine and *CYP2D6*; thiopurines and *TPMT*; simvastatin and *SLCO1B1*; and celecoxib and *CYP2C9*). The example the authors provide of a deferral on a well-known drug-gene pair demonstrates the high quality of the evaluation process for selecting genetic variants, and the ability of the framework to incorporate increasing amounts of new evidence from studies. Furthermore, the sustained attention devoted to the gaps in pharmacogenomic knowledge, such as the limited information we have on the association between rare variants and adverse drug reactions, and the recognition of the need to expand pharmacogenomic studies to pharmacogenetically under-studied populations \[[@B7]\] highlight the comprehensiveness of the framework.

In summary, the work presented by Gharani *et al*. makes a welcome addition to the literature on harnessing the enormous advances in genomics in the clinical setting.
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